Navigation Links
Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Date:10/16/2007

single administration for weeks to months in multiple settings in numerous mid-stage clinical trials for site-specific, moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For more information about Anesiva's leadership in the development of products for pain management, and an overview of the clinical challenges being addressed by its product candidates, go to http://www.anesiva.com.

Forward Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. Forward- looking statements in this press release include matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others: the timing and results of our clinical trials, whether Anesiva is able to manufacture its products on commercially reasonable terms, whether Anesiva can secure FDA approval for the use of Zingo in adults, and the degree to which Zingo gains market acceptance. Actual results may differ materially from those contained in the forward-looking statements in this press release. Additional information concerning these and other risk factors is contained in Anesiva's quarterly report on Form 10-Q for the quarter ended June 30, 2007.

Anesiva undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  BC Technical, the largest nationwide, ... America , Inc., a leading provider of Siemens Nuclear ... long-term agreement naming BC Technical as the authorized provider ... MiE and BC Technical announced today that the ... BC Technical as the service and systems provider for ...
(Date:7/10/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... a quarterly dividend of $0.275 (27.5 cents) per share on ... 1, 2014, to holders of record on July 21, 2014. ... is dedicated to helping people on their path to better ... the United States . Through the company,s more than ...
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( ... "Dental Consumables Market - Global Industry Analysis, Size, Share, ... to their offering. (Logo: ... which are used on patients in order to treat ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... AMSTERDAM, May 31, 2011 Leading events organiser ... UBM), announced details of a new Logistics and Supply ... event dedicated to pharmaceutical contract services and outsourcing. ICSE ... Messe Frankfurt, Germany and is part of the world,s ...
... 2011 Volcano Corporation (NASDAQ: VOLC ), a ... guidance tools designed to enhance the treatment of coronary and ... in the Goldman Sachs 32nd Annual Global Healthcare Conference on ... 2:40 p.m., Pacific Daylight Time (5:40 p.m., Eastern Daylight Time). ...
Cached Medicine Technology:Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 2Logistics and Supply Chain Zone Introduced at ICSE 2011 Event 3
(Date:7/14/2014)... Summer is the best season of the year for ... and other outdoor adventures. The promotional product experts at ... all summer long. The promo product gurus at 4AllPromos have ... imprinted products everyone must have on hand this summer. ... Sunscreen helps protect skin from harmful UV rays produced ...
(Date:7/14/2014)... Crystal Dental has recently announced that it ... been made via LAD Solutions in in order to increase ... made in order to draw in new patients that can ... Crystal Dental offers a variety of services for both routine ... Dental include cosmetic dentistry procedures such as porcelain veneers and ...
(Date:7/13/2014)... 14, 2014 FORT LEE, N.J. – Authors ... modern approach to the science of tooth implants ... This book describes recent advances and techniques in the ... that benefit people who have lost all of their natural ... the first lower subperiosteal implant in 1940. It was ...
(Date:7/13/2014)... Recently, TopDresses100.com, a popular dress company in ... multi-colored Quinceanera dresses to its product line. ... colorful outfits are guaranteed to be quality made. Now, ... off. , TopDresses100.com has a wide variety of elegant ... items are in stock and ready to ship. As ...
(Date:7/13/2014)... July 13, 2014 Manchester United and ... the 2014 Guinness International Champions Cup. The 2014 ICC ... each year because of the talent of it brings in. ... AS Roma will compete in the 2014 event spread across ... 24 with a game between Olympiacos and Milan and will ...
Breaking Medicine News(10 mins):Health News:Why These Three Summer Essentials from 4AllPromos Can Improve Summer 2Health News:Crystal Dental Announces the Opening of New Office Location in Sacramento 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 2Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 3Health News:Authors Leonard I. Linkow and Sheldon Winkler Feature Advancements in Implant Dentistry 4Health News:Cheap Multi-colored Quinceanera Dresses From TopDresses100.com 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3
... Dialysis Corporation of,America (Nasdaq: DCAI ) ... located at the St. Thomas More Nursing and,Rehabilitation Center, ... St.,Thomas More Center, as well as the surrounding community. ... 24 treatment stations and is currently caring for,approximately 145 ...
... Inc., a Boston-based,award-winning medical tourism facilitator, has ... an Indianapolis-based health benefits company to provide,global ... affiliated health plan,in Wisconsin. Healthbase will handle ... WellPoint members. , ...
... and flu,season, which means misery for kids and the parents trying ... asking parents to resist the urge to give children under,the age ... Such drugs can have serious side effects on the smallest ... drowsiness,difficulty breathing and even death. , "Some ...
... 5 Health-conscious consumers who are,tired of taking several ... smaller,more powerful alternative to fish oil supplements in MegaRed(TM) ... fatty acids combined with,powerful antioxidants, and is three times ... softgel per day -- which is about as small ...
... Jan. 5 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) ... updates where amongst other things the company addressed several ... that it has finalized its bilateral negotiations with Slavica ... Chem is a spin off of Renuyu Biochem, a ...
... Soliris(R) INCLINE VILLAGE, Nev., and CHESHIRE, Conn., Jan. 5 ... Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN ) today ... license agreement and settlement agreement that resolve the legal disputes ... PDL,s patents known as the Queen et al. patents. ...
Cached Medicine News:Health News:Dialysis Corporation of America Announces Acquisition of Maryland Dialysis Center 2Health News:Healthbase Collaborates with WellPoint to Bring Affordable Medical Tourism Solutions 2Health News:Caution Urged When Giving Kids Cold and Flu Meds 2Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 2Health News:Three Times More Powerful Than Fish Oil, MegaRed(TM) Omega-3 Krill Oil Now Available Nationwide 3Health News:Hard To Treat Diseases (HTDS) Completes E Europe Merger 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 3
... The table-mounted knee ... exposure for total knee ... flexible, open-frame design allows ... the knee during the ...
... NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2) is a ... predicting acute renal failure with a >90% ... especially in urine, as early as 2 ... an ideal diagnostic marker for acute renal ...
... an assayed quality control material used for ... hemoglobin fractions on CO-Oximeter instrumentation. It provides ... that parallels the human physiologic range for ... available in three (3) levels for monitoring ...
... is an assayed quality control ... measurements of total hemoglobin and ... It is available in three ... performance at varying points within ...
Medicine Products: